MA50069A - Dérivés 1-(4-(isoxazol-5-yl)-1h-pyrazol-1-yl)-2-méthylpropan-2-ol et composés similaires en tant qu'inhibiterus il-7 et ifn-gamma pour le traitement de maladies autoimmune et inflammation chronique - Google Patents

Dérivés 1-(4-(isoxazol-5-yl)-1h-pyrazol-1-yl)-2-méthylpropan-2-ol et composés similaires en tant qu'inhibiterus il-7 et ifn-gamma pour le traitement de maladies autoimmune et inflammation chronique

Info

Publication number: MA50069A
Authority: MA; Morocco
Prior art keywords: inhibiterus; methylpropan; isoxazol; pyrazol; ifn
Prior art date: 2017-09-06

Application number

MA050069A

Other languages

English (en)

Other versions

MA50069B1 (fr

Inventor

Carine Chevrier

Jakob Felding

Manfred Gröppel

Hella Kohlhof

Rolf Andreas Mühler

Stefan Tasler

Daniel Vitt

Mirko Zaja

Original Assignee

Immunic Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-09-06

Filing date

2018-09-06

Publication date

2021-05-05

2018-09-06 Application filed by Immunic Ag filed Critical Immunic Ag

2021-05-05 Publication of MA50069A publication Critical patent/MA50069A/fr

2023-08-31 Publication of MA50069B1 publication Critical patent/MA50069B1/fr

Links

AIIHUEPNMIUVRF-UHFFFAOYSA-N 2-methyl-1-[4-(1,2-oxazol-5-yl)pyrazol-1-yl]propan-2-ol Chemical compound O1N=CC=C1C=1C=NN(C=1)CC(C)(O)C AIIHUEPNMIUVRF-UHFFFAOYSA-N 0.000 title 1
108010002586 Interleukin-7 Proteins 0.000 title 1
230000001363 autoimmune Effects 0.000 title 1
208000037976 chronic inflammation Diseases 0.000 title 1
230000006020 chronic inflammation Effects 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Immunology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

MA50069A 2017-09-06 2018-09-06 Dérivés 1-(4-(isoxazol-5-yl)-1h-pyrazol-1-yl)-2-méthylpropan-2-ol et composés similaires en tant qu'inhibiterus il-7 et ifn-gamma pour le traitement de maladies autoimmune et inflammation chronique MA50069B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP17189652		2017-09-06
PCT/EP2018/073993 WO2019048541A1 (fr)	2017-09-06	2018-09-06	Dérivés de 1-(4-(isoxazol-5-yl)-1 h-pyrazol-1-yl)-2-méthylpropan-2-ol et composés apparentés en tant qu'inhibiteurs d'il-17 et d'ifn-gamma pour le traitement de maladies auto-immunes et d'une inflammation chronique

Publications (2)

Publication Number	Publication Date
MA50069A true MA50069A (fr)	2021-05-05
MA50069B1 MA50069B1 (fr)	2023-08-31

Family

ID=59799324

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA50069A MA50069B1 (fr)	2017-09-06	2018-09-06	Dérivés 1-(4-(isoxazol-5-yl)-1h-pyrazol-1-yl)-2-méthylpropan-2-ol et composés similaires en tant qu'inhibiterus il-7 et ifn-gamma pour le traitement de maladies autoimmune et inflammation chronique

Country Status (26)

Country	Link
US (1)	US11292788B2 (fr)
EP (2)	EP4074708A1 (fr)
JP (2)	JP2020532575A (fr)
KR (1)	KR20200069299A (fr)
CN (1)	CN111433202A (fr)
AU (1)	AU2018330633C1 (fr)
CA (1)	CA3074891A1 (fr)
DK (1)	DK3679034T3 (fr)
ES (1)	ES2925538T3 (fr)
HR (1)	HRP20221042T1 (fr)
HU (1)	HUE059822T2 (fr)
IL (1)	IL273064B2 (fr)
LT (1)	LT3679034T (fr)
MA (1)	MA50069B1 (fr)
MD (1)	MD3679034T2 (fr)
MX (1)	MX2020002571A (fr)
PH (1)	PH12020500461A1 (fr)
PL (1)	PL3679034T3 (fr)
PT (1)	PT3679034T (fr)
RS (1)	RS63532B1 (fr)
SG (1)	SG11202001409UA (fr)
SI (1)	SI3679034T1 (fr)
SM (1)	SMT202200343T1 (fr)
UA (1)	UA126689C2 (fr)
WO (1)	WO2019048541A1 (fr)
ZA (1)	ZA202001179B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI3679034T1 (sl) *	2017-09-06	2022-11-30	Immunic Ag	Derivati 1-(4-(izoksazol-5-il)-1H-pirazol-1-il)-2-metilpropan-2-ola in sorodne spojine kot zaviralci IL-7 in IFN-GAMA za zdravljenje avtoimunskih bolezni in kroničnega vnetja
WO2023281097A1 (fr)	2021-07-09	2023-01-12	Immunic Ag	Méthodes de traitement du cancer
CN113683505A (zh) *	2021-09-29	2021-11-23	厦门大华本安化工安全研究院有限公司	一种含氧代环丁基的羧酸酯类化合物的制备方法
EP4508049A1 (fr)	2022-04-14	2025-02-19	Immunic AG	Agonistes inverses de rorgamma/rorgammat deutérés
WO2023232870A1 (fr)	2022-05-31	2023-12-07	Immunic Ag	Modulateurs de rorg/rorgt pour le traitement d'infections virales de type covid-19
CN119192167B (zh) *	2024-11-28	2025-03-21	英矽智能科技(上海)有限公司	一类抑制il-17的化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012101263A1 (fr)	2011-01-28	2012-08-02	4Sc Discovery Gmbh	Inhibition de l'il17 et de l'ifn-gamma dans le traitement d'une inflammation autoimmune
US8592456B2 (en) *	2011-01-28	2013-11-26	4Sc Discovery Gmbh	IL17 and IFN-gamma inhibition for the treatment of autoimmune inflammation
SI3679034T1 (sl) *	2017-09-06	2022-11-30	Immunic Ag	Derivati 1-(4-(izoksazol-5-il)-1H-pirazol-1-il)-2-metilpropan-2-ola in sorodne spojine kot zaviralci IL-7 in IFN-GAMA za zdravljenje avtoimunskih bolezni in kroničnega vnetja

2018
- 2018-09-06 SI SI201830741T patent/SI3679034T1/sl unknown
- 2018-09-06 AU AU2018330633A patent/AU2018330633C1/en not_active Ceased
- 2018-09-06 MA MA50069A patent/MA50069B1/fr unknown
- 2018-09-06 HR HRP20221042TT patent/HRP20221042T1/hr unknown
- 2018-09-06 WO PCT/EP2018/073993 patent/WO2019048541A1/fr not_active Ceased
- 2018-09-06 PL PL18762111.5T patent/PL3679034T3/pl unknown
- 2018-09-06 KR KR1020207009871A patent/KR20200069299A/ko not_active Ceased
- 2018-09-06 LT LTEPPCT/EP2018/073993T patent/LT3679034T/lt unknown
- 2018-09-06 PT PT187621115T patent/PT3679034T/pt unknown
- 2018-09-06 UA UAA202002206A patent/UA126689C2/uk unknown
- 2018-09-06 EP EP22176185.1A patent/EP4074708A1/fr not_active Withdrawn
- 2018-09-06 CN CN201880058056.9A patent/CN111433202A/zh active Pending
- 2018-09-06 DK DK18762111.5T patent/DK3679034T3/da active
- 2018-09-06 RS RS20220796A patent/RS63532B1/sr unknown
- 2018-09-06 CA CA3074891A patent/CA3074891A1/fr active Pending
- 2018-09-06 SG SG11202001409UA patent/SG11202001409UA/en unknown
- 2018-09-06 JP JP2020514532A patent/JP2020532575A/ja active Pending
- 2018-09-06 HU HUE18762111A patent/HUE059822T2/hu unknown
- 2018-09-06 ES ES18762111T patent/ES2925538T3/es active Active
- 2018-09-06 MD MDE20200707T patent/MD3679034T2/ro unknown
- 2018-09-06 SM SM20220343T patent/SMT202200343T1/it unknown
- 2018-09-06 US US16/644,581 patent/US11292788B2/en active Active
- 2018-09-06 MX MX2020002571A patent/MX2020002571A/es unknown
- 2018-09-06 EP EP18762111.5A patent/EP3679034B1/fr active Active
2020
- 2020-02-25 ZA ZA2020/01179A patent/ZA202001179B/en unknown
- 2020-03-04 IL IL273064A patent/IL273064B2/en unknown
- 2020-03-06 PH PH12020500461A patent/PH12020500461A1/en unknown
2022
- 2022-12-23 JP JP2022206807A patent/JP2023052060A/ja active Pending

Also Published As

Publication number	Publication date
HRP20221042T1 (hr)	2022-11-11
IL273064A (en)	2020-04-30
CA3074891A1 (fr)	2019-03-14
JP2020532575A (ja)	2020-11-12
MA50069B1 (fr)	2023-08-31
DK3679034T3 (da)	2022-08-29
NZ761897A (en)	2023-10-27
BR112020004332A2 (pt)	2020-09-08
RU2020112319A3 (fr)	2022-02-07
SMT202200343T1 (it)	2022-11-18
PH12020500461A1 (en)	2021-01-11
AU2018330633B2 (en)	2021-02-25
MX2020002571A (es)	2020-10-01
KR20200069299A (ko)	2020-06-16
LT3679034T (lt)	2022-09-12
AU2018330633C1 (en)	2022-02-24
JP2023052060A (ja)	2023-04-11
MD3679034T2 (ro)	2022-10-31
UA126689C2 (uk)	2023-01-11
PL3679034T3 (pl)	2022-11-14
IL273064B2 (en)	2023-06-01
RS63532B1 (sr)	2022-09-30
RU2020112319A (ru)	2021-10-06
US11292788B2 (en)	2022-04-05
SG11202001409UA (en)	2020-03-30
AU2018330633A1 (en)	2020-03-05
US20210061796A1 (en)	2021-03-04
EP3679034A1 (fr)	2020-07-15
EP4074708A1 (fr)	2022-10-19
CN111433202A (zh)	2020-07-17
ES2925538T3 (es)	2022-10-18
ZA202001179B (en)	2023-03-29
SI3679034T1 (sl)	2022-11-30
HUE059822T2 (hu)	2022-12-28
WO2019048541A1 (fr)	2019-03-14
EP3679034B1 (fr)	2022-06-01
PT3679034T (pt)	2022-08-29

Publication	Publication Date	Title
MA50069A (fr)	2021-05-05	Dérivés 1-(4-(isoxazol-5-yl)-1h-pyrazol-1-yl)-2-méthylpropan-2-ol et composés similaires en tant qu'inhibiterus il-7 et ifn-gamma pour le traitement de maladies autoimmune et inflammation chronique
MA51200A (fr)	2020-10-07	Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA55325A (fr)	2022-04-27	Composés pour le traitement de maladies pd-l1
EP3866781A4 (fr)	2022-11-09	Nouvelles compositions pour le traitement de maladies inflammatoires
EP3704108A4 (fr)	2021-08-25	Composés et compositions pour le traitement de troubles hématologiques
EP3448875A4 (fr)	2020-04-08	Compositions pour le traitement de maladies
EP3448987A4 (fr)	2020-05-27	Compositions pour le traitement de maladies
MA45481A (fr)	2018-04-18	Utilisation d'exosomes pour le traitement de maladies
MA56019A (fr)	2022-04-06	Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA49279A (fr)	2020-02-05	Compositions d'anticorps optimisées pour le traitement de troubles oculaires
MA52873A (fr)	2021-04-21	Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
EP3621973A4 (fr)	2021-10-27	Composés pour la prévention et le traitement de maladies et leur utilisation
EP3340982A4 (fr)	2019-03-27	Composés pour le traitement de troubles immunitaires et inflammatoires
MA45089A (fr)	2019-04-10	Utilisation d'indazoles 2-substitués pour le traitement et la prophylaxie de maladies auto-immunes
EP3463315A4 (fr)	2020-01-15	Compositions et méthodes d'utilisation de nintédanib pour le traitement de maladies oculaires à néovascularisation anormale
EP3328864A4 (fr)	2019-01-09	Composés et compositions thérapeutiques pour le traitement de troubles sociaux et de troubles liés à la toxicomanie
EP3829569A4 (fr)	2022-04-27	Formulations de spinosyne pour le traitement de maladies oculaires et faciaux provoquées par demodex
MA50391A (fr)	2021-04-21	Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires
EP3645039A4 (fr)	2021-05-05	Utilisation d'anticorps anti-fam19a5 pour le traitement de la fibrose
EP3352749A4 (fr)	2019-09-04	Composés et compositions pour le traitement de troubles oculaires
MA51056A (fr)	2020-10-14	Compositions et méthodes pour le traitement d'affections métaboliques
EP3630102A4 (fr)	2021-04-14	Formulations pour le traitement d'un trouble de stress post-traumatique
EP3496662A4 (fr)	2019-10-30	Protéine dérivée de la soie pour le traitement d'une inflammation
EP3661553A4 (fr)	2021-06-02	Méthodes et compositions pour le traitement des maladies à dépôts amyloïdes
MA55218A (fr)	2022-01-12	Eskétamine pour le traitement de la dépression